Published in Vaccine Weekly, May 11th, 2005
Study 1: Researchers report the impact of p53-based immunization on primary chemically-induced tumors in a recent issue of the International Journal of Cancer.
According to a study from the United States, "In mice as well as humans, cytotoxic T lymphocytes (CTL) specific for wild-type-sequence (wt) p53 peptides have been shown to react against a wide range of tumors, but not normal cells. As such, they are attractive candidates for developing broadly applicable cancer vaccines. Of particular interest is the potential of using p53-based vaccines in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly